Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study

Vaccine

Volumn 33, Issue 39, 2015, Pages 5217-5224

  Perrett, Kirsten P ^a   McVernon, Jodie ^a   Richmond, Peter C ^b   Marshall, Helen ^c   Nissen, Michael ^d   August, Allison ^e   Percell, Sandra ^e   Toneatto, Daniela ^f   Nolan, Terry ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Novartis Vaccines and Diagnostics Inc   (United States)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Adolescence; Immunity; Immunization; Neisseria meningitidis; Serogroup B meningococcal vaccine

Indexed keywords

BACTERIAL ANTIGEN; COMPLEMENT; FACTOR H BINDING PROTEIN; MENINGOCOCCAL SEROGROUP B VACCINE; MENINGOCOCCUS VACCINE; NEISSERIA ADHESIN A; NEISSERIA HEPARIN BINDING ANTIGEN; PORIN A; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; 4CMENB VACCINE; BACTERIUM ANTIBODY;

ADOLESCENT; ARTHRALGIA; ARTICLE; AUSTRALIA; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CANADA; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; OUTER MEMBRANE; OUTER MEMBRANE VESICLE; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SERUM BACTERICIDAL ACTIVITY; SERUM BACTERICIDAL ANTIBODY ASSAY; SINGLE BLIND PROCEDURE; SWELLING; VACCINATION; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNIZATION; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; AUSTRALIA; BLOOD BACTERICIDAL ACTIVITY; CANADA; CHILD; COMPLEMENT SYSTEM PROTEINS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; TREATMENT OUTCOME;

EID: 84941734398     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.103     Document Type: Article

References (41)

1. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972, 126:514-521.
2. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
3. Lahra M.M., Enriquez R.P. Annual report of the Australian Meningococcal Surveillance Programme, 2011. Commun Dis Intell Q Report 2012, 36:E251-E262.
4. Halperin S.A., Bettinger J.A., Greenwood B., Harrison L.H., Jelfs J., Ladhani S.N., et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012, 30(Suppl. 2):B26-B36.
5. Safadi M.A., Cintra O.A. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010, 32:263-271.
6. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 2013, 32:e20-e25.
7. England PH. Invasive meningococcal disease (laboratory reports in England): 2013/2014 annual data by epidemiological year, vol 9(3), 23 Jan 2015.
8. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14:195-207. [discussion 8-10].
9. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338:1093-1096.
10. Holst J., Feiring B., Naess L.M., Norheim G., Kristiansen P., Hoiby E.A., et al. The concept of tailor-made, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005, 23:2202-2205.
11. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
12. O'Hallahan J., McNicholas A., Galloway Y., O'Leary E., Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009, 122:48-59.
13. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
14. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
15. Arnold R. Poisson regression modelling of the effectiveness of the meningococcal B vaccine (MeNZB) updated results to December 2008, Technical Report New Zealand Ministry of Health 2010, 90.
16. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
17. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
18. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.
19. Toneatto D., Ismaili S., Ypma E., Vienken K., Oster P., Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccines 2011, 7:646-653.
20. Toneatto D., Oster P., deBoer A.C., Emerson A., Santos G.F., Ypma E., et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccines 2011, 7:781-791.
21. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
22. Giuliani M.M., Biolchi A., Serruto D., Ferlicca F., Vienken K., Oster P., et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010, 28:5023-5030.
23. Borrow R., Southern J., Andrews N., Peake N., Rahim R., Acuna M., et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001, 19:3043-3050.
24. Madore D.V., Johnson-Kraines C.L., Rothstein E.P., Smith D.H. Kinetics of antibody response to Haemophilus influenzae type b vaccines. Pennridge Pediatric Associates. Curr Med Res Opin 1999, 15:105-112.
25. de Voer R.M., van der Klis F.R., Engels C.W., Schepp R.M., van de Kassteele J., Sanders E.A., et al. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. Vaccine 2009, 27:6974-6982.
26. Dull P., Bai X., Bazaz R., et al. Serum bactericidal antibody levels following quadrivalent conjugate (MenACWY-CRM) or serogroup B (4CMenB) meningococcal vaccines in a Phase 3 study to evaluate the effect of vaccination on pharyngeal carriage of N. meningitidis in young adults 2013, Meningitis and Septicaemia in Children and Adults 2013, London, England, UK.
27. Jackson C., Lennon D.R., Sotutu V.T., Yan J., Stewart J.M., Reid S., et al. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch Dis Child. 2009, 94:745-751.
28. Wong S., Lennon D., Jackson C., Stewart J., Reid S., Crengle S., et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007, 26:345-350.
29. Hosking J., Rasanathan K., Mow F.C., Jackson C., Martin D., O'Hallahan J., et al. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol 2007, 14:1393-1399.
30. Jackson C., Lennon D., Wong S., Yan J., Stewart J., Reid S., et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child 2011, 96:744-751.
31. Holst J., Feiring B., Fuglesang J.E., Hoiby E.A., Nokleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21:734-737.
32. Galloway Y., Stehr-Green P., McNicholas A., O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009, 38:413-418.
33. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
34. Read Rea Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMENB) meningococcal vaccine on meningococcal carriage in English university students. ESPID 2013.
35. ®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe 2013.
36. JCVI Position statement on use of Bexsero meningococcal B vaccine in the UK 2014.
37. Frosi G., Biolchi A., Lo Sapio M., Rigat F., Gilchrist S., Lucidarme J., et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013, 31:4968-4974.
38. Marshall H.S., Richmond P.C., Nissen M.D., Wouters A., Baber J., Jiang Q., et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013, 31:1569-1575.
39. Richmond P.C., Marshall H.S., Nissen M.D., Jiang Q., Jansen K.U., Garces-Sanchez M., et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:597-607.
40. Vesikari T.D.-D.J., Ostergaard L., et al. Safety, tolerability, and immunogenicity of an investigational meningococcal serogroup B bivalent rLP2086 vaccine when administered in regimens of 2 or 3 doses in healthy adolescent subjects aged 11 to 18 years. Poster presented at: 9th Conference of the Meningitis Research Foundation, November 5-6, London, United Kingdom, 2013 2013.
41. January 23, 2015 Approval Letter - BEXSERO, http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm431446.htm.